Login / Signup

Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.

Rabab El EitAbdul Rahman ItaniFarah NassarNagham RasbiehMark JabbourAhmad SantinaGhazi ZaatariFrançois-Xavier MahonAli BazarbachiRihab R Nasr
Published in: Cancer (2019)
Collectively, the ATO/IFN strategy has been demonstrated to have the potential to lead to durable remissions in TKI-resistant CML preclinical models and to overcome various TKI-specific mechanisms of resistance.
Keyphrases
  • chronic myeloid leukemia
  • dendritic cells
  • cell therapy
  • immune response
  • drinking water
  • heavy metals
  • stem cells
  • risk assessment
  • mesenchymal stem cells
  • tyrosine kinase